MAST3: a novel IBD risk factor that modulates TLR4 signaling.

Area of Science:

• Genetics
• Immunology
• Molecular Biology

Background:

• Inflammatory bowel disease (IBD) is a chronic condition influenced by genetic factors and the innate immune system.
• Previous genome-wide studies identified a significant locus (IBD6) on chromosome 19p associated with IBD susceptibility.

Purpose of the Study:

• To identify the specific causal genetic variant within the IBD6 locus contributing to IBD.
• To investigate the role of the microtubule-associated serine/threonine-protein kinase gene-3 (MAST3) in IBD pathogenesis.

Main Methods:

• A two-stage genome-wide association study involving genotyping of single-nucleotide polymorphisms (SNPs) in a large cohort of IBD patients.
• Expression assays to determine MAST3 expression in relevant immune cells.
• Functional studies involving MAST3 gene knockdown to assess its impact on NF-kappaB signaling.

Main Results:

• A significant association was found with an intronic variant (rs273506) in the MAST3 gene (pooled P=1.8 x 10(-4)).
• A correlated non-synonymous coding variant (rs8108738) in MAST3 was also associated with IBD.
• MAST3 is highly expressed in antigen-presenting cells and lymphocytes, and its knockdown reduced Toll-like receptor-4-dependent NF-kappaB activity.

Conclusions:

• The study implicates MAST3 as a potential susceptibility gene for IBD.
• MAST3 plays a role in modulating innate immune responses, specifically NF-kappaB signaling, which is relevant to IBD pathogenesis.